This meta-analysis evaluated the impact of adding DPP-4 inhibitors to insulin therapy, focusing on glycemic control as assessed by HbA1c, insulin requirements, and the implications for patients with type 1 diabetes. This evidence concerns the gene DPP4 and type 1 diabetes mellitus.